ACRP CCRC Exam Prep Questions

A patient cannot recall the name of the heart condition medication he took a few years ago. This is important information for deciding whether the patient may be enrolled in a clinical trial (IC/EC). Whats your best course of action?

Who has ultimate trial responsibility for each subject?

A trial subject suffers from severe repeat headaches. Should this adverse event be reported to the IRB?

What statements are true concerning an adverse drug reaction?

What Adverse Events (AEs) are Serious Adverse Events (SAEs)?

During a study visit, a patient tells the investigator that she visited an emergency room and received intensive treatment for allergic bronchospasm. Since the patient was in the emergency room for only three hours, the investigator did not assess the event as serious. Is this a correct assessment?

What data points minimally need to be reported by the site when reporting an SAE, so that the sponsor can process the event?

During a visit with the investigator, a subject reported feeling heart palpitations for a brief period of time during the previous evening. The heart palpitations resolved without reoccurrence. The investigator considered these symptoms to be unrelated to the study drug. The next day, the subject told a fellow student that he felt tired and was planning on taking a nap. Later, the subject was found dead. A preliminary report from the medical examiner indicated the subject died of pulmonary embolism. What should your next course of action be?

When asked by a regulatory body why they received SAE related information on 12/2013 from an incident that occurred in 5/2013, the sponsor explained the reason being they received the trial-related SAE information from the investigator in 12/2013. Is the sponsor correct in only holding the investigator accountable for their late reporting?

A trial subject in a cardiology trial is admitted to the hospital with a heart attack. The investigator considers this event possibly related to the study drug even though this is not listed in the IB as a potential adverse reaction. How would the investigator report this event to the sponsor?

A 22-year-old male was entered into a clinical study for the treatment of schizophrenia. The study drug was administered orally, BID. One week later, the subject visited the investigator complaining of severe sore throat. The IB lists this as an occurrence reported by 1% of subjects receiving the drug. How should this sore throat be classified?

In regards to AE and ADR reporting, what statements are true?

What determines the causality of an adverse event?

Which term best describes the cyclical process that involves the Plan, Do, Check, Act activities?

Which term best describes an independent assessment of completed work to ensure it will meet applicable quality standards?

Which term best describes the activities done to ensure quality output?

Which term requires structure and a definition of acceptable standards of performance?

%1ACRP CCRC Exam Prep Questions%2%3These practice questions are designed to help you prepare for the ACRP CCRC exam. They cover a range of topics related to clinical trials and the responsibilities of a clinical research coordinator. Test your knowledge and see how well you do!%4Q1: What are expected or possible consequences of over-estimation of recruitment potential?A1: - The trial will overrun its projected timeline- The recruitment period will be prolonged and more sites may be needed- The study will not have sufficient data within the required timeframe and will be stopped because of lack of budgetQ2: What should be the first consideration when conducting a clinical trial?A2: Subject welfareQ3: When is the investigator allowed to deviate from the protocol?A3: When there is an immediate hazard to a patient.Q4: If the investigator wanted to deviate from the protocol for an immediate hazard to a patient, according to ICH E6 guidelines who would they need to report the deviation and rationale to, if appropriate?A4: - The Sponsor- IRB/IEC- Regulatory AuthoritiesQ5: Which conditions should be fulfilled when enrolling a subject into your trial?A5: - Subject meets all inclusion criteria- Subject has given written informed consentQ6: Youve been delegated to handle the storage and inventory of IP. The study drug must be stored below 25C/77F. On a summer Monday morning you discover that the temperature recording machine in the storage room has failed so you dont know what the temperature has been over the weekend. You check the current temperature; its 24C/75F. What should you do?A6: - Contact the Sponsor, explain what happened and ask for instructions- Set up a site staff meeting to conduct a root cause analysisQ7: A protocol amendment was issued for a trial. Your site received IRB approval for the amendment and wants to implement the increase in PO dose for your trial subjects as identified in the amendment trial subjects. As delegated consenting duties you must re-consent trial subjects before being able to administer the adjusted dose. You decide to only re-consent trial subjects who are still taking the IP and not from the subjects who already completed their drug intake period. Is this allowed according to the E6 Guideline for GCP?A7: No, these subjects are still enrolled in the trial and therefore need to be updated on any changes to the protocol.Q8: A trial subject informs you she no longer wants to participate in the trial. What should your course of action be?A8: You ask if the patient wishes to share the reason why she wants to leave the trial. If not, you exclude the subject from the trial immediately.Q9: A patient cannot recall the name of the heart condition medication he took a few years ago. This is important information for deciding whether the patient may be enrolled in a clinical trial (IC/EC). Whats your best course of action?A9: You attempt to retrieve the patients medical history by contacting previous caregivers and wait for additional information before enrollment.Q10: Who has ultimate trial responsibility for each subject?A10: The principal investigator.Q11: A trial subject suffers from severe repeat headaches. Should this adverse event be reported to the IRB?A11: NoQ12: What statements are true concerning an adverse drug reaction?A12: - All noxious and unintended responses to a medicinal product related to any dose should be considered as an ADR- An ADR suggests a relationship to trial medication- All ADRs must be documentedQ13: What Adverse Events (AEs) are Serious Adverse Events (SAEs)?A13: - Any AE that results in death- Any AE that results in inpatient hospitalization- Any AE that is a congenital anomalyQ14: During a study visit, a patient tells the investigator that she visited an emergency room and received intensive treatment for allergic bronchospasm. Since the patient was in the emergency room for only three hours, the investigator did not assess the event as serious. Is this a correct assessment?A14: No, this would be a medically important event and should be considered seriousQ15: What data points minimally need to be reported by the site when reporting an SAE, so that the sponsor can process the event?A15: Identification of event, product, and trial subjectQ16: During a visit with the investigator, a subject reported feeling heart palpitations for a brief period of time during the previous evening. The heart palpitations resolved without reoccurrence. The investigator considered these symptoms to be unrelated to the study drug. The next day, the subject told a fellow student that he felt tired and was planning on taking a nap. Later, the subject was found dead. A preliminary report from the medical examiner indicated the subject died of pulmonary embolism. What should your next course of action be?A16: - Record these events in the case report form- Immediately notify the sponsor about serious adverse eventsQ17: When asked by a regulatory body why they received SAE related information on 12/2013 from an incident that occurred in 5/2013, the sponsor explained the reason being they received the trial-related SAE information from the investigator in 12/2013. Is the sponsor correct in only holding the investigator accountable for their late reporting?A17: No, the sponsor should support the conduct QC activities with the sites to help them ensure timely SAE reporting.Q18: A trial subject in a cardiology trial is admitted to the hospital with a heart attack. The investigator considers this event possibly related to the study drug even though this is not listed in the IB as a potential adverse reaction. How would the investigator report this event to the sponsor?A18: An unexpected, serious adverse eventQ19: A 22-year-old male was entered into a clinical study for the treatment of schizophrenia. The study drug was administered orally, BID. One week later, the subject visited the investigator complaining of severe sore throat. The IB lists this as an occurrence reported by 1% of subjects receiving the drug. How should this sore throat be classified?A19: - An adverse event- An adverse drug reactionQ20: In regards to AE and ADR reporting, what statements are true?A20: - All ADRs are AEs, but not all AEs are ADRs- Worsening in pre-existing medical conditions is an AE- Preplanned hospitalization is usually not an SAEQ21: What determines the causality of an adverse event?A21: The investigatorQ22: Which term best describes the cyclical process that involves the Plan, Do, Check, Act activities?A22: Quality improvementQ23: Which term best describes an independent assessment of completed work to ensure it will meet applicable quality standards?A23: Quality assuranceQ24: Which term best describes the activities done to ensure quality output?A24: Quality controlQ25: Which term requires structure and a definition of acceptable standards of performance?A25: Quality management(Note: This is only a partial list of questions. Please generate the remaining questions and answers.)

%1ACRP CCRC Exam Prep Questions%2%3These practice questions are designed to help you prepare for the ACRP CCRC exam. They cover a range of topics related to clinical trials and the responsibilities of a clinical research coordinator. Test your knowledge and see how well you do!%4Q1: What are expected or possible consequences of over-estimation of recruitment potential?A1: - The trial will overrun its projected timeline- The recruitment period will be prolonged and more sites may be needed- The study will not have sufficient data within the required timeframe and will be stopped because of lack of budgetQ2: What should be the first consideration when conducting a clinical trial?A2: Subject welfareQ3: When is the investigator allowed to deviate from the protocol?A3: When there is an immediate hazard to a patient.Q4: If the investigator wanted to deviate from the protocol for an immediate hazard to a patient, according to ICH E6 guidelines who would they need to report the deviation and rationale to, if appropriate?A4: - The Sponsor- IRB/IEC- Regulatory AuthoritiesQ5: Which conditions should be fulfilled when enrolling a subject into your trial?A5: - Subject meets all inclusion criteria- Subject has given written informed consentQ6: Youve been delegated to handle the storage and inventory of IP. The study drug must be stored below 25C/77F. On a summer Monday morning you discover that the temperature recording machine in the storage room has failed so you dont know what the temperature has been over the weekend. You check the current temperature; its 24C/75F. What should you do?A6: - Contact the Sponsor, explain what happened and ask for instructions- Set up a site staff meeting to conduct a root cause analysisQ7: A protocol amendment was issued for a trial. Your site received IRB approval for the amendment and wants to implement the increase in PO dose for your trial subjects as identified in the amendment trial subjects. As delegated consenting duties you must re-consent trial subjects before being able to administer the adjusted dose. You decide to only re-consent trial subjects who are still taking the IP and not from the subjects who already completed their drug intake period. Is this allowed according to the E6 Guideline for GCP?A7: No, these subjects are still enrolled in the trial and therefore need to be updated on any changes to the protocol.Q8: A trial subject informs you she no longer wants to participate in the trial. What should your course of action be?A8: You ask if the patient wishes to share the reason why she wants to leave the trial. If not, you exclude the subject from the trial immediately.Q9: A patient cannot recall the name of the heart condition medication he took a few years ago. This is important information for deciding whether the patient may be enrolled in a clinical trial (IC/EC). Whats your best course of action?A9: You attempt to retrieve the patients medical history by contacting previous caregivers and wait for additional information before enrollment.Q10: Who has ultimate trial responsibility for each subject?A10: The principal investigator.Q11: A trial subject suffers from severe repeat headaches. Should this adverse event be reported to the IRB?A11: NoQ12: What statements are true concerning an adverse drug reaction?A12: - All noxious and unintended responses to a medicinal product related to any dose should be considered as an ADR- An ADR suggests a relationship to trial medication- All ADRs must be documentedQ13: What Adverse Events (AEs) are Serious Adverse Events (SAEs)?A13: - Any AE that results in death- Any AE that results in inpatient hospitalization- Any AE that is a congenital anomalyQ14: During a study visit, a patient tells the investigator that she visited an emergency room and received intensive treatment for allergic bronchospasm. Since the patient was in the emergency room for only three hours, the investigator did not assess the event as serious. Is this a correct assessment?A14: No, this would be a medically important event and should be considered seriousQ15: What data points minimally need to be reported by the site when reporting an SAE, so that the sponsor can process the event?A15: Identification of event, product, and trial subjectQ16: During a visit with the investigator, a subject reported feeling heart palpitations for a brief period of time during the previous evening. The heart palpitations resolved without reoccurrence. The investigator considered these symptoms to be unrelated to the study drug. The next day, the subject told a fellow student that he felt tired and was planning on taking a nap. Later, the subject was found dead. A preliminary report from the medical examiner indicated the subject died of pulmonary embolism. What should your next course of action be?A16: - Record these events in the case report form- Immediately notify the sponsor about serious adverse eventsQ17: When asked by a regulatory body why they received SAE related information on 12/2013 from an incident that occurred in 5/2013, the sponsor explained the reason being they received the trial-related SAE information from the investigator in 12/2013. Is the sponsor correct in only holding the investigator accountable for their late reporting?A17: No, the sponsor should support the conduct QC activities with the sites to help them ensure timely SAE reporting.Q18: A trial subject in a cardiology trial is admitted to the hospital with a heart attack. The investigator considers this event possibly related to the study drug even though this is not listed in the IB as a potential adverse reaction. How would the investigator report this event to the sponsor?A18: An unexpected, serious adverse eventQ19: A 22-year-old male was entered into a clinical study for the treatment of schizophrenia. The study drug was administered orally, BID. One week later, the subject visited the investigator complaining of severe sore throat. The IB lists this as an occurrence reported by 1% of subjects receiving the drug. How should this sore throat be classified?A19: - An adverse event- An adverse drug reactionQ20: In regards to AE and ADR reporting, what statements are true?A20: - All ADRs are AEs, but not all AEs are ADRs- Worsening in pre-existing medical conditions is an AE- Preplanned hospitalization is usually not an SAEQ21: What determines the causality of an adverse event?A21: The investigatorQ22: Which term best describes the cyclical process that involves the Plan, Do, Check, Act activities?A22: Quality improvementQ23: Which term best describes an independent assessment of completed work to ensure it will meet applicable quality standards?A23: Quality assuranceQ24: Which term best describes the activities done to ensure quality output?A24: Quality controlQ25: Which term requires structure and a definition of acceptable standards of performance?A25: Quality management(Note: This is only a partial list of questions. Please generate the remaining questions and answers.)

%1ACRP CCRC Exam Prep Questions%2%3These practice questions are designed to help you prepare for the ACRP CCRC exam. They cover a range of topics related to clinical trials and the responsibilities of a clinical research coordinator. Test your knowledge and see how well you do!%4Q1: What are expected or possible consequences of over-estimation of recruitment potential?A1: - The trial will overrun its projected timeline- The recruitment period will be prolonged and more sites may be needed- The study will not have sufficient data within the required timeframe and will be stopped because of lack of budgetQ2: What should be the first consideration when conducting a clinical trial?A2: Subject welfareQ3: When is the investigator allowed to deviate from the protocol?A3: When there is an immediate hazard to a patient.Q4: If the investigator wanted to deviate from the protocol for an immediate hazard to a patient, according to ICH E6 guidelines who would they need to report the deviation and rationale to, if appropriate?A4: - The Sponsor- IRB/IEC- Regulatory AuthoritiesQ5: Which conditions should be fulfilled when enrolling a subject into your trial?A5: - Subject meets all inclusion criteria- Subject has given written informed consentQ6: Youve been delegated to handle the storage and inventory of IP. The study drug must be stored below 25C/77F. On a summer Monday morning you discover that the temperature recording machine in the storage room has failed so you dont know what the temperature has been over the weekend. You check the current temperature; its 24C/75F. What should you do?A6: - Contact the Sponsor, explain what happened and ask for instructions- Set up a site staff meeting to conduct a root cause analysisQ7: A protocol amendment was issued for a trial. Your site received IRB approval for the amendment and wants to implement the increase in PO dose for your trial subjects as identified in the amendment trial subjects. As delegated consenting duties you must re-consent trial subjects before being able to administer the adjusted dose. You decide to only re-consent trial subjects who are still taking the IP and not from the subjects who already completed their drug intake period. Is this allowed according to the E6 Guideline for GCP?A7: No, these subjects are still enrolled in the trial and therefore need to be updated on any changes to the protocol.Q8: A trial subject informs you she no longer wants to participate in the trial. What should your course of action be?A8: You ask if the patient wishes to share the reason why she wants to leave the trial. If not, you exclude the subject from the trial immediately.Q9: A patient cannot recall the name of the heart condition medication he took a few years ago. This is important information for deciding whether the patient may be enrolled in a clinical trial (IC/EC). Whats your best course of action?A9: You attempt to retrieve the patients medical history by contacting previous caregivers and wait for additional information before enrollment.Q10: Who has ultimate trial responsibility for each subject?A10: The principal investigator.Q11: A trial subject suffers from severe repeat headaches. Should this adverse event be reported to the IRB?A11: NoQ12: What statements are true concerning an adverse drug reaction?A12: - All noxious and unintended responses to a medicinal product related to any dose should be considered as an ADR- An ADR suggests a relationship to trial medication- All ADRs must be documentedQ13: What Adverse Events (AEs) are Serious Adverse Events (SAEs)?A13: - Any AE that results in death- Any AE that results in inpatient hospitalization- Any AE that is a congenital anomalyQ14: During a study visit, a patient tells the investigator that she visited an emergency room and received intensive treatment for allergic bronchospasm. Since the patient was in the emergency room for only three hours, the investigator did not assess the event as serious. Is this a correct assessment?A14: No, this would be a medically important event and should be considered seriousQ15: What data points minimally need to be reported by the site when reporting an SAE, so that the sponsor can process the event?A15: Identification of event, product, and trial subjectQ16: During a visit with the investigator, a subject reported feeling heart palpitations for a brief period of time during the previous evening. The heart palpitations resolved without reoccurrence. The investigator considered these symptoms to be unrelated to the study drug. The next day, the subject told a fellow student that he felt tired and was planning on taking a nap. Later, the subject was found dead. A preliminary report from the medical examiner indicated the subject died of pulmonary embolism. What should your next course of action be?A16: - Record these events in the case report form- Immediately notify the sponsor about serious adverse eventsQ17: When asked by a regulatory body why they received SAE related information on 12/2013 from an incident that occurred in 5/2013, the sponsor explained the reason being they received the trial-related SAE information from the investigator in 12/2013. Is the sponsor correct in only holding the investigator accountable for their late reporting?A17: No, the sponsor should support the conduct QC activities with the sites to help them ensure timely SAE reporting.Q18: A trial subject in a cardiology trial is admitted to the hospital with a heart attack. The investigator considers this event possibly related to the study drug even though this is not listed in the IB as a potential adverse reaction. How would the investigator report this event to the sponsor?A18: An unexpected, serious adverse eventQ19: A 22-year-old male was entered into a clinical study for the treatment of schizophrenia. The study drug was administered orally, BID. One week later, the subject visited the investigator complaining of severe sore throat. The IB lists this as an occurrence reported by 1% of subjects receiving the drug. How should this sore throat be classified?A19: - An adverse event- An adverse drug reactionQ20: In regards to AE and ADR reporting, what statements are true?A20: - All ADRs are AEs, but not all AEs are ADRs- Worsening in pre-existing medical conditions is an AE- Preplanned hospitalization is usually not an SAEQ21: What determines the causality of an adverse event?A21: The investigatorQ22: Which term best describes the cyclical process that involves the Plan, Do, Check, Act activities?A22: Quality improvementQ23: Which term best describes an independent assessment of completed work to ensure it will meet applicable quality standards?A23: Quality assuranceQ24: Which term best describes the activities done to ensure quality output?A24: Quality controlQ25: Which term requires structure and a definition of acceptable standards of performance?A25: Quality management(Note: This is only a partial list of questions. Please generate the remaining questions and answers.)

%1ACRP CCRC Exam Prep Questions%2%3These practice questions are designed to help you prepare for the ACRP CCRC exam. They cover a range of topics related to clinical trials and the responsibilities of a clinical research coordinator. Test your knowledge and see how well you do!%4Q1: What are expected or possible consequences of over-estimation of recruitment potential?A1: - The trial will overrun its projected timeline- The recruitment period will be prolonged and more sites may be needed- The study will not have sufficient data within the required timeframe and will be stopped because of lack of budgetQ2: What should be the first consideration when conducting a clinical trial?A2: Subject welfareQ3: When is the investigator allowed to deviate from the protocol?A3: When there is an immediate hazard to a patient.Q4: If the investigator wanted to deviate from the protocol for an immediate hazard to a patient, according to ICH E6 guidelines who would they need to report the deviation and rationale to, if appropriate?A4: - The Sponsor- IRB/IEC- Regulatory AuthoritiesQ5: Which conditions should be fulfilled when enrolling a subject into your trial?A5: - Subject meets all inclusion criteria- Subject has given written informed consentQ6: Youve been delegated to handle the storage and inventory of IP. The study drug must be stored below 25C/77F. On a summer Monday morning you discover that the temperature recording machine in the storage room has failed so you dont know what the temperature has been over the weekend. You check the current temperature; its 24C/75F. What should you do?A6: - Contact the Sponsor, explain what happened and ask for instructions- Set up a site staff meeting to conduct a root cause analysisQ7: A protocol amendment was issued for a trial. Your site received IRB approval for the amendment and wants to implement the increase in PO dose for your trial subjects as identified in the amendment trial subjects. As delegated consenting duties you must re-consent trial subjects before being able to administer the adjusted dose. You decide to only re-consent trial subjects who are still taking the IP and not from the subjects who already completed their drug intake period. Is this allowed according to the E6 Guideline for GCP?A7: No, these subjects are still enrolled in the trial and therefore need to be updated on any changes to the protocol.Q8: A trial subject informs you she no longer wants to participate in the trial. What should your course of action be?A8: You ask if the patient wishes to share the reason why she wants to leave the trial. If not, you exclude the subject from the trial immediately.Q9: A patient cannot recall the name of the heart condition medication he took a few years ago. This is important information for deciding whether the patient may be enrolled in a clinical trial (IC/EC). Whats your best course of action?A9: You attempt to retrieve the patients medical history by contacting previous caregivers and wait for additional information before enrollment.Q10: Who has ultimate trial responsibility for each subject?A10: The principal investigator.Q11: A trial subject suffers from severe repeat headaches. Should this adverse event be reported to the IRB?A11: NoQ12: What statements are true concerning an adverse drug reaction?A12: - All noxious and unintended responses to a medicinal product related to any dose should be considered as an ADR- An ADR suggests a relationship to trial medication- All ADRs must be documentedQ13: What Adverse Events (AEs) are Serious Adverse Events (SAEs)?A13: - Any AE that results in death- Any AE that results in inpatient hospitalization- Any AE that is a congenital anomalyQ14: During a study visit, a patient tells the investigator that she visited an emergency room and received intensive treatment for allergic bronchospasm. Since the patient was in the emergency room for only three hours, the investigator did not assess the event as serious. Is this a correct assessment?A14: No, this would be a medically important event and should be considered seriousQ15: What data points minimally need to be reported by the site when reporting an SAE, so that the sponsor can process the event?A15: Identification of event, product, and trial subjectQ16: During a visit with the investigator, a subject reported feeling heart palpitations for a brief period of time during the previous evening. The heart palpitations resolved without reoccurrence. The investigator considered these symptoms to be unrelated to the study drug. The next day, the subject told a fellow student that he felt tired and was planning on taking a nap. Later, the subject was found dead. A preliminary report from the medical examiner indicated the subject died of pulmonary embolism. What should your next course of action be?A16: - Record these events in the case report form- Immediately notify the sponsor about serious adverse eventsQ17: When asked by a regulatory body why they received SAE related information on 12/2013 from an incident that occurred in 5/2013, the sponsor explained the reason being they received the trial-related SAE information from the investigator in 12/2013. Is the sponsor correct in only holding the investigator accountable for their late reporting?A17: No, the sponsor should support the conduct QC activities with the sites to help them ensure timely SAE reporting.Q18: A trial subject in a cardiology trial is admitted to the hospital with a heart attack. The investigator considers this event possibly related to the study drug even though this is not listed in the IB as a potential adverse reaction. How would the investigator report this event to the sponsor?A18: An unexpected, serious adverse eventQ19: A 22-year-old male was entered into a clinical study for the treatment of schizophrenia. The study drug was administered orally, BID. One week later, the subject visited the investigator complaining of severe sore throat. The IB lists this as an occurrence reported by 1% of subjects receiving the drug. How should this sore throat be classified?A19: - An adverse event- An adverse drug reactionQ20: In regards to AE and ADR reporting, what statements are true?A20: - All ADRs are AEs, but not all AEs are ADRs- Worsening in pre-existing medical conditions is an AE- Preplanned hospitalization is usually not an SAEQ21: What determines the causality of an adverse event?A21: The investigatorQ22: Which term best describes the cyclical process that involves the Plan, Do, Check, Act activities?A22: Quality improvementQ23: Which term best describes an independent assessment of completed work to ensure it will meet applicable quality standards?A23: Quality assuranceQ24: Which term best describes the activities done to ensure quality output?A24: Quality controlQ25: Which term requires structure and a definition of acceptable standards of performance?A25: Quality management(Note: This is only a partial list of questions. Please generate the remaining questions and answers.)

%1ACRP CCRC Exam Prep Questions%2%3These practice questions are designed to help you prepare for the ACRP CCRC exam. They cover a range of topics related to clinical trials and the responsibilities of a clinical research coordinator. Test your knowledge and see how well you do!%4Q1: What are expected or possible consequences of over-estimation of recruitment potential?A1: - The trial will overrun its projected timeline- The recruitment period will be prolonged and more sites may be needed- The study will not have sufficient data within the required timeframe and will be stopped because of lack of budgetQ2: What should be the first consideration when conducting a clinical trial?A2: Subject welfareQ3: When is the investigator allowed to deviate from the protocol?A3: When there is an immediate hazard to a patient.Q4: If the investigator wanted to deviate from the protocol for an immediate hazard to a patient, according to ICH E6 guidelines who would they need to report the deviation and rationale to, if appropriate?A4: - The Sponsor- IRB/IEC- Regulatory AuthoritiesQ5: Which conditions should be fulfilled when enrolling a subject into your trial?A5: - Subject meets all inclusion criteria- Subject has given written informed consentQ6: Youve been delegated to handle the storage and inventory of IP. The study drug must be stored below 25C/77F. On a summer Monday morning you discover that the temperature recording machine in the storage room has failed so you dont know what the temperature has been over the weekend. You check the current temperature; its 24C/75F. What should you do?A6: - Contact the Sponsor, explain what happened and ask for instructions- Set up a site staff meeting to conduct a root cause analysisQ7: A protocol amendment was issued for a trial. Your site received IRB approval for the amendment and wants to implement the increase in PO dose for your trial subjects as identified in the amendment trial subjects. As delegated consenting duties you must re-consent trial subjects before being able to administer the adjusted dose. You decide to only re-consent trial subjects who are still taking the IP and not from the subjects who already completed their drug intake period. Is this allowed according to the E6 Guideline for GCP?A7: No, these subjects are still enrolled in the trial and therefore need to be updated on any changes to the protocol.Q8: A trial subject informs you she no longer wants to participate in the trial. What should your course of action be?A8: You ask if the patient wishes to share the reason why she wants to leave the trial. If not, you exclude the subject from the trial immediately.Q9: A patient cannot recall the name of the heart condition medication he took a few years ago. This is important information for deciding whether the patient may be enrolled in a clinical trial (IC/EC). Whats your best course of action?A9: You attempt to retrieve the patients medical history by contacting previous caregivers and wait for additional information before enrollment.Q10: Who has ultimate trial responsibility for each subject?A10: The principal investigator.Q11: A trial subject suffers from severe repeat headaches. Should this adverse event be reported to the IRB?A11: NoQ12: What statements are true concerning an adverse drug reaction?A12: - All noxious and unintended responses to a medicinal product related to any dose should be considered as an ADR- An ADR suggests a relationship to trial medication- All ADRs must be documentedQ13: What Adverse Events (AEs) are Serious Adverse Events (SAEs)?A13: - Any AE that results in death- Any AE that results in inpatient hospitalization- Any AE that is a congenital anomalyQ14: During a study visit, a patient tells the investigator that she visited an emergency room and received intensive treatment for allergic bronchospasm. Since the patient was in the emergency room for only three hours, the investigator did not assess the event as serious. Is this a correct assessment?A14: No, this would be a medically important event and should be considered seriousQ15: What data points minimally need to be reported by the site when reporting an SAE, so that the sponsor can process the event?A15: Identification of event, product, and trial subjectQ16: During a visit with the investigator, a subject reported feeling heart palpitations for a brief period of time during the previous evening. The heart palpitations resolved without reoccurrence. The investigator considered these symptoms to be unrelated to the study drug. The next day, the subject told a fellow student that he felt tired and was planning on taking a nap. Later, the subject was found dead. A preliminary report from the medical examiner indicated the subject died of pulmonary embolism. What should your next course of action be?A16: - Record these events in the case report form- Immediately notify the sponsor about serious adverse eventsQ17: When asked by a regulatory body why they received SAE related information on 12/2013 from an incident that occurred in 5/2013, the sponsor explained the reason being they received the trial-related SAE information from the investigator in 12/2013. Is the sponsor correct in only holding the investigator accountable for their late reporting?A17: No, the sponsor should support the conduct QC activities with the sites to help them ensure timely SAE reporting.Q18: A trial subject in a cardiology trial is admitted to the hospital with a heart attack. The investigator considers this event possibly related to the study drug even though this is not listed in the IB as a potential adverse reaction. How would the investigator report this event to the sponsor?A18: An unexpected, serious adverse eventQ19: A 22-year-old male was entered into a clinical study for the treatment of schizophrenia. The study drug was administered orally, BID. One week later, the subject visited the investigator complaining of severe sore throat. The IB lists this as an occurrence reported by 1% of subjects receiving the drug. How should this sore throat be classified?A19: - An adverse event- An adverse drug reactionQ20: In regards to AE and ADR reporting, what statements are true?A20: - All ADRs are AEs, but not all AEs are ADRs- Worsening in pre-existing medical conditions is an AE- Preplanned hospitalization is usually not an SAEQ21: What determines the causality of an adverse event?A21: The investigatorQ22: Which term best describes the cyclical process that involves the Plan, Do, Check, Act activities?A22: Quality improvementQ23: Which term best describes an independent assessment of completed work to ensure it will meet applicable quality standards?A23: Quality assuranceQ24: Which term best describes the activities done to ensure quality output?A24: Quality controlQ25: Which term requires structure and a definition of acceptable standards of performance?A25: Quality management(Note: This is only a partial list of questions. Please generate the remaining questions and answers.)

%1ACRP CCRC Exam Prep Questions%2%3These practice questions are designed to help you prepare for the ACRP CCRC exam. They cover a range of topics related to clinical trials and the responsibilities of a clinical research coordinator. Test your knowledge and see how well you do!%4Q1: What are expected or possible consequences of over-estimation of recruitment potential?A1: - The trial will overrun its projected timeline- The recruitment period will be prolonged and more sites may be needed- The study will not have sufficient data within the required timeframe and will be stopped because of lack of budgetQ2: What should be the first consideration when conducting a clinical trial?A2: Subject welfareQ3: When is the investigator allowed to deviate from the protocol?A3: When there is an immediate hazard to a patient.Q4: If the investigator wanted to deviate from the protocol for an immediate hazard to a patient, according to ICH E6 guidelines who would they need to report the deviation and rationale to, if appropriate?A4: - The Sponsor- IRB/IEC- Regulatory AuthoritiesQ5: Which conditions should be fulfilled when enrolling a subject into your trial?A5: - Subject meets all inclusion criteria- Subject has given written informed consentQ6: Youve been delegated to handle the storage and inventory of IP. The study drug must be stored below 25C/77F. On a summer Monday morning you discover that the temperature recording machine in the storage room has failed so you dont know what the temperature has been over the weekend. You check the current temperature; its 24C/75F. What should you do?A6: - Contact the Sponsor, explain what happened and ask for instructions- Set up a site staff meeting to conduct a root cause analysisQ7: A protocol amendment was issued for a trial. Your site received IRB approval for the amendment and wants to implement the increase in PO dose for your trial subjects as identified in the amendment trial subjects. As delegated consenting duties you must re-consent trial subjects before being able to administer the adjusted dose. You decide to only re-consent trial subjects who are still taking the IP and not from the subjects who already completed their drug intake period. Is this allowed according to the E6 Guideline for GCP?A7: No, these subjects are still enrolled in the trial and therefore need to be updated on any changes to the protocol.Q8: A trial subject informs you she no longer wants to participate in the trial. What should your course of action be?A8: You ask if the patient wishes to share the reason why she wants to leave the trial. If not, you exclude the subject from the trial immediately.Q9: A patient cannot recall the name of the heart condition medication he took a few years ago. This is important information for deciding whether the patient may be enrolled in a clinical trial (IC/EC). Whats your best course of action?A9: You attempt to retrieve the patients medical history by contacting previous caregivers and wait for additional information before enrollment.Q10: Who has ultimate trial responsibility for each subject?A10: The principal investigator.Q11: A trial subject suffers from severe repeat headaches. Should this adverse event be reported to the IRB?A11: NoQ12: What statements are true concerning an adverse drug reaction?A12: - All noxious and unintended responses to a medicinal product related to any dose should be considered as an ADR- An ADR suggests a relationship to trial medication- All ADRs must be documentedQ13: What Adverse Events (AEs) are Serious Adverse Events (SAEs)?A13: - Any AE that results in death- Any AE that results in inpatient hospitalization- Any AE that is a congenital anomalyQ14: During a study visit, a patient tells the investigator that she visited an emergency room and received intensive treatment for allergic bronchospasm. Since the patient was in the emergency room for only three hours, the investigator did not assess the event as serious. Is this a correct assessment?A14: No, this would be a medically important event and should be considered seriousQ15: What data points minimally need to be reported by the site when reporting an SAE, so that the sponsor can process the event?A15: Identification of event, product, and trial subjectQ16: During a visit with the investigator, a subject reported feeling heart palpitations for a brief period of time during the previous evening. The heart palpitations resolved without reoccurrence. The investigator considered these symptoms to be unrelated to the study drug. The next day, the subject told a fellow student that he felt tired and was planning on taking a nap. Later, the subject was found dead. A preliminary report from the medical examiner indicated the subject died of pulmonary embolism. What should your next course of action be?A16: - Record these events in the case report form- Immediately notify the sponsor about serious adverse eventsQ17: When asked by a regulatory body why they received SAE related information on 12/2013 from an incident that occurred in 5/2013, the sponsor explained the reason being they received the trial-related SAE information from the investigator in 12/2013. Is the sponsor correct in only holding the investigator accountable for their late reporting?A17: No, the sponsor should support the conduct QC activities with the sites to help them ensure timely SAE reporting.Q18: A trial subject in a cardiology trial is admitted to the hospital with a heart attack. The investigator considers this event possibly related to the study drug even though this is not listed in the IB as a potential adverse reaction. How would the investigator report this event to the sponsor?A18: An unexpected, serious adverse eventQ19: A 22-year-old male was entered into a clinical study for the treatment of schizophrenia. The study drug was administered orally, BID. One week later, the subject visited the investigator complaining of severe sore throat. The IB lists this as an occurrence reported by 1% of subjects receiving the drug. How should this sore throat be classified?A19: - An adverse event- An adverse drug reactionQ20: In regards to AE and ADR reporting, what statements are true?A20: - All ADRs are AEs, but not all AEs are ADRs- Worsening in pre-existing medical conditions is an AE- Preplanned hospitalization is usually not an SAEQ21: What determines the causality of an adverse event?A21: The investigatorQ22: Which term best describes the cyclical process that involves the Plan, Do, Check, Act activities?A22: Quality improvementQ23: Which term best describes an independent assessment of completed work to ensure it will meet applicable quality standards?A23: Quality assuranceQ24: Which term best describes the activities done to ensure quality output?A24: Quality controlQ25: Which term requires structure and a definition of acceptable standards of performance?A25: Quality management(Note: This is only a partial list of questions. Please generate the remaining questions and answers.)

%1ACRP CCRC Exam Prep Questions%2%3These practice questions are designed to help you prepare for the ACRP CCRC exam. They cover a range of topics related to clinical trials and the responsibilities of a clinical research coordinator. Test your knowledge and see how well you do!%4Q1: What are expected or possible consequences of over-estimation of recruitment potential?A1: - The trial will overrun its projected timeline- The recruitment period will be prolonged and more sites may be needed- The study will not have sufficient data within the required timeframe and will be stopped because of lack of budgetQ2: What should be the first consideration when conducting a clinical trial?A2: Subject welfareQ3: When is the investigator allowed to deviate from the protocol?A3: When there is an immediate hazard to a patient.Q4: If the investigator wanted to deviate from the protocol for an immediate hazard to a patient, according to ICH E6 guidelines who would they need to report the deviation and rationale to, if appropriate?A4: - The Sponsor- IRB/IEC- Regulatory AuthoritiesQ5: Which conditions should be fulfilled when enrolling a subject into your trial?A5: - Subject meets all inclusion criteria- Subject has given written informed consentQ6: Youve been delegated to handle the storage and inventory of IP. The study drug must be stored below 25C/77F. On a summer Monday morning you discover that the temperature recording machine in the storage room has failed so you dont know what the temperature has been over the weekend. You check the current temperature; its 24C/75F. What should you do?A6: - Contact the Sponsor, explain what happened and ask for instructions- Set up a site staff meeting to conduct a root cause analysisQ7: A protocol amendment was issued for a trial. Your site received IRB approval for the amendment and wants to implement the increase in PO dose for your trial subjects as identified in the amendment trial subjects. As delegated consenting duties you must re-consent trial subjects before being able to administer the adjusted dose. You decide to only re-consent trial subjects who are still taking the IP and not from the subjects who already completed their drug intake period. Is this allowed according to the E6 Guideline for GCP?A7: No, these subjects are still enrolled in the trial and therefore need to be updated on any changes to the protocol.Q8: A trial subject informs you she no longer wants to participate in the trial. What should your course of action be?A8: You ask if the patient wishes to share the reason why she wants to leave the trial. If not, you exclude the subject from the trial immediately.Q9: A patient cannot recall the name of the heart condition medication he took a few years ago. This is important information for deciding whether the patient may be enrolled in a clinical trial (IC/EC). Whats your best course of action?A9: You attempt to retrieve the patients medical history by contacting previous caregivers and wait for additional information before enrollment.Q10: Who has ultimate trial responsibility for each subject?A10: The principal investigator.Q11: A trial subject suffers from severe repeat headaches. Should this adverse event be reported to the IRB?A11: NoQ12: What statements are true concerning an adverse drug reaction?A12: - All noxious and unintended responses to a medicinal product related to any dose should be considered as an ADR- An ADR suggests a relationship to trial medication- All ADRs must be documentedQ13: What Adverse Events (AEs) are Serious Adverse Events (SAEs)?A13: - Any AE that results in death- Any AE that results in inpatient hospitalization- Any AE that is a congenital anomalyQ14: During a study visit, a patient tells the investigator that she visited an emergency room and received intensive treatment for allergic bronchospasm. Since the patient was in the emergency room for only three hours, the investigator did not assess the event as serious. Is this a correct assessment?A14: No, this would be a medically important event and should be considered seriousQ15: What data points minimally need to be reported by the site when reporting an SAE, so that the sponsor can process the event?A15: Identification of event, product, and trial subjectQ16: During a visit with the investigator, a subject reported feeling heart palpitations for a brief period of time during the previous evening. The heart palpitations resolved without reoccurrence. The investigator considered these symptoms to be unrelated to the study drug. The next day, the subject told a fellow student that he felt tired and was planning on taking a nap. Later, the subject was found dead. A preliminary report from the medical examiner indicated the subject died of pulmonary embolism. What should your next course of action be?A16: - Record these events in the case report form- Immediately notify the sponsor about serious adverse eventsQ17: When asked by a regulatory body why they received SAE related information on 12/2013 from an incident that occurred in 5/2013, the sponsor explained the reason being they received the trial-related SAE information from the investigator in 12/2013. Is the sponsor correct in only holding the investigator accountable for their late reporting?A17: No, the sponsor should support the conduct QC activities with the sites to help them ensure timely SAE reporting.Q18: A trial subject in a cardiology trial is admitted to the hospital with a heart attack. The investigator considers this event possibly related to the study drug even though this is not listed in the IB as a potential adverse reaction. How would the investigator report this event to the sponsor?A18: An unexpected, serious adverse eventQ19: A 22-year-old male was entered into a clinical study for the treatment of schizophrenia. The study drug was administered orally, BID. One week later, the subject visited the investigator complaining of severe sore throat. The IB lists this as an occurrence reported by 1% of subjects receiving the drug. How should this sore throat be classified?A19: - An adverse event- An adverse drug reactionQ20: In regards to AE and ADR reporting, what statements are true?A20: - All ADRs are AEs, but not all AEs are ADRs- Worsening in pre-existing medical conditions is an AE- Preplanned hospitalization is usually not an SAEQ21: What determines the causality of an adverse event?A21: The investigatorQ22: Which term best describes the cyclical process that involves the Plan, Do, Check, Act activities?A22: Quality improvementQ23: Which term best describes an independent assessment of completed work to ensure it will meet applicable quality standards?A23: Quality assuranceQ24: Which term best describes the activities done to ensure quality output?A24: Quality controlQ25: Which term requires structure and a definition of acceptable standards of performance?A25: Quality management(Note: This is only a partial list of questions. Please generate the remaining questions and answers.)